Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study-Reference-Cited by-同舟云学术

Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study

Published:2020-12 Issue: Volume:150 Page:164-171
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Zeng Jian,Mao Wei-Min,Chen Qi-Xun,Luo Tao-Bo,Wu Yi-Long^ORCID,Zhou Qing^ORCID,Yang Xue-Ning,Yan Hong-Hong,Zhong Wen-Zhao,Wang Qun,Xu Song-Tao,Wu Lin^ORCID,Shen Yi,Liu Yong-Yu,Chen Chun,Cheng Ying,Xu Lin,Wang Jun,Fei Ke,Li Xiao-Fei,Li Jian,Huang Cheng,Liu Zhi-Dong,Xu Shun,Chen Ke-Neng,Xu Shi-Dong,Liu Lun-Xu,Yu Ping,Wang Bu-Hai,Ma Hai-Tao

Funder

Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine

National Health and Family Planning Commission of People’s Republic of China

Guangzhou Science and Technology Bureau

AstraZeneca China

Chinese Thoracic Oncology Group

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. NCCN Clinical Practice Guidelines in Oncology Non-small Cell Lung Cancer (version5.2019),2019